Issuance Strengthens Commercialization Strategy of Company’s Gene-Based Endometriosis Diagnostics and Therapeutics
Salt Lake City, UT – December 28, 2017- Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today the issuance of U.S. patent 9,840,738 directed to treating patients genetically predisposed to endometriosis.
Endometriosis, a common gynecologic disorder estimated to affect 1 in 10 women in their reproductive years – equates to approximately 176 million women in the world. U.S. patent 9,840,738, builds on the coverage provided by previously issued US patent 8,932,993.
“This technology brings a significant opportunity for PRED and to the healthcare market, assisting women and their physicians in designing a course of care that places women on the most appropriate therapy at the earliest possible stage of disease progression,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to the therapeutic products PRED intends to bring to market.”
Bradley Robinson described the claims of U.S. patent 9,840,738 as covering any treatment of endometriosis in women, whether symptomatic or not, having any one (or more) of approximately 1,400 endometriosis-associated genetic markers.
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding Company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and firstname.lastname@example.org.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.